Urine HPV Testing for Cervical Cancer Screening Among Women Living With HIV in South Africa
Clinical Performance Validation of Urine HPV Testing for Cervical Cancer Screening Among Women Living With HIV in South Africa
UNC Lineberger Comprehensive Cancer Center
300 participants
May 11, 2023
INTERVENTIONAL
Conditions
Summary
The purpose of this study explores the usefulness of urine samples for cervical cancer screening in human immunodeficiency virus (HIV)-infected women. Cervical cancer occurs when women are infected with the human papillomavirus (HPV), which can cause changes in the cells that lead to cervical precancer and, eventually, cervical cancer if untreated. However, urine HPV testing has not been well validated low- and middle-income country settings, with no data available to guide its use in HIV-infected women.
Eligibility
Inclusion Criteria4
- In order to participate in this study a subject must meet all of the eligibility criteria outlined below.
- Confirmed HIV-1 infection
- Age 25 years and older.
- Be willing and able to provide written informed consent.
Exclusion Criteria6
- Pregnant or intend to become pregnant within 90 days of enrollment
- Have been screened for cervical cancer within the preceding year (365 days)
- Have an active sexually transmitted infection (STI; women may participate once treated)
- Have a surgically absent cervix
- Have a history of cervical cancer
- have been vaccinated against HPV.
Interventions
Human papillomavirus (HPV) testing in urine sample.
Human papillomavirus (HPV) testing in self-collected cervicovaginal specimen sample.
Human papillomavirus (HPV) testing in healthcare provider collected cervicovaginal specimen sample.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05413798